PRA Health Sciences EBIT

PRA Health Sciences (PRAH) currently reports a EBIT of $300M as of March 2021. That compares with $350M in the prior-year period — down 13.8% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore PRA Health Sciences's EBIT history and peer comparisons.

PRA Health Sciences's EBIT decreased from $350M to $300M — a 13.8% year-over-year decrease (period ending March 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PRA Health Sciences's EBIT of $300M is lower than the Healthcare sector average of $110B. That is roughly 99.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

PRA Health Sciences reported $300M in EBIT as of March 2021. That compares with $350M in the prior-year period — down 13.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $300M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for PRA Health Sciences, and consider following PRAH for alerts when major investors trade the stock.